Publications:

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.

Plos One

S Poirier, HA Hamouda, L Villeneuve, A Demers, G Mayer

Publication Date: 2016

Variant appearance in text: PCSK9: F379A

PMID: 27280970

View BVdb publication page

Emerging Roles of PCSK9: More Than a One-Trick Pony.

Arteriosclerosis, Thrombosis, And Vascular Biology

KJ Moore, IJ Goldberg

Publication Date: 2016-02

Variant appearance in text: PCSK9: F379A

PMID: 26819460

View BVdb publication page

Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.

The Journal Of Biological Chemistry

QT Le, M Blanchet, NG Seidah, P Labonté

Publication Date: 2015-09-18

Variant appearance in text: PCSK9: F379A

PMID: 26195630

View BVdb publication page

Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.

The Journal Of Biological Chemistry

Y Zhang, C Eigenbrot, L Zhou, S Shia, W Li, C Quan, J Tom, P Moran, P Di Lello, NJ Skelton, M Kong-Beltran, A Peterson, D Kirchhofer

Publication Date: 2014-01-10

Variant appearance in text: PCSK9: F379A

PMID: 24225950

View BVdb publication page

Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

The Journal Of Biological Chemistry

RM DeVay, DL Shelton, H Liang

Publication Date: 2013-04-12

Variant appearance in text: PCSK9: F379A

PMID: 23430252

View BVdb publication page

Alternative transcript annotations: